MOUSE ANTI-YELLOW FEVER VIRUS NS1 ANTIBODY (HH7)

Mouse anti Yellow Fever Virus NS1 antibody is specific for the NS1 protein of Yellow Fever virus. It demonstrates negligible cross-reactivity with NS1 proteins from other flaviviruses, including Dengue virus, Zika Virus, West Nile Virus and Japanese Encephalitis virus. No cross-reactivity is seen with Chikungunya virus proteins (E1, E2 and C). This mouse anti Yellow Fever virus NS1 antibody is suitable for use in direct ELISA, Sandwich ELISA as a capture antibody and in Western Blot (in non-reducing conditions).

PRODUCT DETAILS – MOUSE ANTI-YELLOW FEVER VIRUS NS1 ANTIBODY (HH7)

• Mouse anti-Yellow Fever virus NS1 protein monoclonal IgG1 antibody (clone HH7).
• Greater than 95% purity by SDS-PAGE and buffered in PBS, pH7.4.

BACKGROUND

The NS1 protein is a major non-structural protein expressed by the Yellow Fever Virus. The NS1 monomer is a glycosylated protein of approximately 45kD, which associates with lipids and forms a homodimer inside infected cells. It is necessary for viral replication, and is also secreted into the extracellular space as a hexameric lipoprotein particle, which is involved in immune evasion and pathogenesis by interacting with components from both the innate and adaptive immune systems, as well as other host factors. NS1 is one of the major antigenic markers for viral infection with Yellow Fever. A recent publication by Ricciardo-Jorge et al has highlighted the utility of measuring NS1 in detection of YFV infection.

Yellow fever is an acute hemorrhagic disease caused by the yellow fever virus (YFV), which is a member of the Flaviviridae family of viruses. Clinical symptoms of the disease include fever, muscle pain, nausea and vomiting. In a small percentage of patients, the liver and kidneys are affected leading to jaundice, and in some cases death. In the sylvatic cycle, the virus is transmitted to non-human primates via mosquitoes of the Haemagogus and Sabethes genera. Whereas the Aedes aegypti mosquito is responsible for the transmission of YFV to humans in urban areas. Yellow fever virus is endemic in tropical areas of Africa and Central/South America where the vector is widespread.

In the late 1930’s a safe and effective attenuated vaccine was developed against the YFV, which confers long-term immunity. Since its introduction, the vaccine has been used successfully to immunize individuals in areas where YFV is endemic.

Diagnosis of yellow fever is complicated by the fact that early symptoms of the infection can be confused with other haemorrhagic diseases including Dengue. Differential diagnosis is therefore an important consideration in areas where other flaviviruses such as Dengue and Zika co-circulate.